The global human growth hormone drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Somatotropin, or human growth hormone, is a peptide hormone that promotes growth, cell reproduction, and cell regeneration. The pituitary gland does not manufacture enough concentrations of human growth hormones in humans, resulting in growth hormone insufficiency. Subcutaneous injections of recombinant human growth hormones are used to treat this deficiency. Growth hormone insufficiency can also be caused by genetic illnesses including Prader-Willi syndrome and Turner syndrome, which can lead to delayed puberty and shorter-than-average height. The development of recombinant human growth hormone treatments, the rise in pituitary dysfunction cases, and the rise in off-label use of human growth hormones are all key factors driving the market growth.

During the forecast period, the turner syndrome segment is expected to have a significant market share in the global human growth hormone drug market. Turner syndrome is a female-specific chromosomal disease that is characterized by the deletion of one of the X chromosomes, either partially or completely. Turner syndrome is characterized by a wide neck and a receding or indistinct hairline, as well as a proclivity for high blood pressure, mild eye difficulties, drooping eyelids, and an underactive thyroid gland. The market is expected to propel as various public and private organizations raise awareness about the early diagnosis and treatment of Turner syndrome. For instance, Turner Syndrome Support Society UK, Turner Syndrome Society of the US, and Turner Syndrome Foundation, mark "Turner Syndrome Awareness Month" in February every year and have started a nationwide effort to raise awareness about the condition.

The key players operating in the global human growth hormone drug market include Eli Lilly and Co., Novo Nordisk A/S, and Pfizer Inc., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, Pfizer Inc. began a Phase III research trial in February 2021 to assess the efficacy and safety of somatropin in a group of Japanese patients with Prader-Willi Syndrome (PWS). In October 2020, Erasmus Medical Center, in collaboration with Pfizer, the Foundation for Prader-Willi Research, and the Prader-Willi Fonds, launched a Phase III clinical trial to evaluate the impact of growth hormone treatment (Genotropin) on physical and psychosocial health in adults with Prader-Willi syndrome who are 30 years or older.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Application 
• By Distribution Channel

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Eli Lilly and Co., Novo Nordisk A/S, and Pfizer Inc., among others.

• Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Human Growth Hormone Drug Market Report by Segment

By Application

• Growth Hormone Deficiency
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Other 

By Distribution Channel

• Hospitals and Retail Pharmacies
• Online Pharmacies

Global Human Growth Hormone Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific 

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa